

**QIBA PET-Amyloid Biomarker Committee**  
**Friday, October 8, 2021, at 9 AM CT**  
*Call Summary*

**In attendance:**

*Dawn Matthews, MS, MBA (Co-chair)* Nancy Obuchowski, PhD  
Norman Foster, MD Jean-Luc Vanderheyden, PhD  
Adriaan Lammertsma, PhD Dean F. Wong, MD, PhD  
Jonathan McConathy, MD, PhD

**RSNA**

Julie Lisiecki

**Moderator:** Ms. Matthews

**The following were discussed:**

- Uncertainty of Aducanumab clinical trials
- New therapy drugs for the treatment of Alzheimer's
- Steps need for Profile Technical Confirmation
- Pursuit of Profile harmonization and dissemination efforts with ADNI, pharma, academic institutions, and CROs
  - Including more phantom models
- Harmonization with ADNI
- Calibration
- Recommendations requested re: outcomes from ADNI discussions
- News item: Retinal scanning may be another avenue to evaluate amyloid

**Next steps**

- Ms. Matthews to list key highlights for the best opportunities for harmonization: recommendations requested
- Ms. Matthews and Dr. Foster to schedule a call with Dr. Koeppe to discuss the ADNI-QIBA gap analysis
  - Dr. Wong to be included
- Ms. Matthews to reach out to Dr. Seibyl regarding introduction to Invicro
- BC discussion on how to handle resistance to Profile requirements
- Produce an online questionnaire with scoring capability, modeled after FDG-PET BC
- Aim to resolve all outstanding issues before the end of 2021

**Action items (ongoing)**

- Dr. Lammertsma to share citations from Alzheimer's research
- Dr. Smith or Ms. Matthews to add a Profile note indicating that data are simulated
- Ms. Matthews to reformat the Profile checklist from Excel to Word
- Co-chairs to respond to Mr. O'Donnell's suggestions

**Next call – Nov 12<sup>th</sup> at 9 am CT**